Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Menu
Professors
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Nikhil George, MD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Natalie Neu, MD, MPH
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Nicolas Chomont, PhD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Nwora Lance Okeke, MD, MPH
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Nichole Klatt, PhD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Nadine J. Kaslow, PhD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Nancy S. Reau, MD
University of California San Francisco
Professor of Medicine, Emeritus
San Francisco, CA
Page 39 of 39
« First
«
...
10
20
30
...
35
36
37
38
39
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Practice Question of the Week
August 18, 2026: Current Efficacy Data on Long-Acting Cabotegravir/Rilpivirine
The LATA (Long-Acting Treatment in Adolescents) trial evaluated long-acting injectable cabotegravir plus rilpivirine (LA CAB/RPV) every 8 weeks versus daily oral dolutegravir/lamivudine/tenofovir disoproxil fumarate (DTG/3TC/TDF) in virologically suppressed adolescents with HIV in sub-Saharan Africa. Which of the following best describes the efficacy of LA CAB/RPV based on the 96-week results of this trial?
A. LA CAB/RPV was noninferior to DTG/3TC/TDF but did not demonstrate superiority
B. LA CAB/RPV demonstrated superiority over DTG/3TC/TDF by significantly reducing the rate of confirmed viral rebound (ie, 2 consecutive plasma HIV RNA levels ≥ 50 copies/mL)
C. LA CAB/RPV was noninferior to DTG/3TC/TDF but differences in the emergence of resistance mutations limited its overall advantage
D. LA CAB/RPV failed to demonstrate noninferiority compared with DTG/3TC/TDF
View the On-Demand Webinar
View Archived Questions
Leave Feedback
Subscribe
CLOSE